Combination of *BRCA* deep targeted sequencing and shallow whole genome sequencing to detect homologous recombination deficiency in ovarian cancer

Thien-Phuc Hoang Nguyen^{1,2#}, Nam HB Tran^{1,2#}, Tien Anh Nguyen^{1,2}, My TT Ngo^{1,2}, Anh Duong Doan^{1,2}, Du Quyen Nguyen^{1,2}, Hung Sang Tang^{1,2}, Duy Sinh Nguyen^{1,2}, Cam Tu Nguyen Thi^{1,2}, Thanh Thuy Do Thi¹, Hoai-Nghia Nguyen^{1,2}, Hoa Giang^{1,2}, Lan N Tu^{1,2}

¹ Medical Genetics Institute, Ho Chi Minh city, Vietnam

² Gene Solutions, Ho Chi Minh city, Vietnam

[#]These authors contributed equally to this work

Corresponding authors:

Lan N Tu: Medical Genetics Institute and Gene Solutions, Ho Chi Minh city, Vietnam (<u>lantu@genesolutions.vn</u>)

Table S1. Patient demographics

Characteristic	77 (100%)
Age at diagnosis (range), years	54 (21 – 85)
>50	47 (61.0%)
≤50	30 (39%)
Subtype (N, %)	
High-grade serous	22 (28.6%)
Endometrioid	4 (5.2%)
Mucinous	1 (1.3%)
Unknown	50 (64.9%)
Stage (N, %)	
I	6 (7.8%)
II	6 (7.8%)
III-IV	65 (84.4%)

ID	BRCA1/2 clinically significant mutation		Instability score		HRD	
	Mutation	VAF	Conclusion	wGI	Conclusion	status
S01	ND		NEG	-16	NEG	NEG
S02	ND		NEG	3	NEG	NEG
S03	ND		NEG	1	POS	POS
S04	ND		NEG	3	POS	POS
S05	ND		NEG	-10	NEG	NEG
S06	ND		NEG	-7	NEG	NEG
S07	ND		NEG	3	NEG	NEG
S08	ND		NEG	2	POS	POS
S09	BRCA2: 3033Nfs*11	38%	POS	-18	NEG	POS
S10	ND		NEG	-12	NEG	NEG
S11	ND		NEG	-16	NEG	NEG
S12	ND		NEG	-19	NEG	NEG
S13	ND		NEG	11	POS	POS
S14	BRCA1:Q1779Nfs*14	70%	POS	11	POS	POS
S15	ND		NEG	12	POS	POS
S16	ND		NEG	14	POS	POS
S17	ND		NEG	-13	NEG	NEG
S18	ND		NEG	-17	NEG	NEG
S19	ND		NEG	-18	NEG	NEG
S20	ND		NEG	0	POS	POS
S21	ND		NEG	1	POS	POS
S22	BRCA1:R1751*	64.1%	POS	14	POS	POS
S23	ND		NEG	5	POS	POS
S24	BRCA1:P871Vfs*31	54%	POS	-5	NEG	POS
S25	ND		NEG	-5	NEG	NEG
S26	ND		NEG	10	POS	POS
S27	ND		NEG	5	POS	POS
S28	ND		NEG	-11	NEG	NEG
S29	ND		NEG	11	POS	POS
S30	ND		NEG	1	POS	POS
S31	BRCA1:Q1779Nfs*14	79%	POS	12	POS	POS
S32	ND		NEG	-5	NEG	NEG
S33	ND		NEG	14	POS	POS
S34	BRCA1:C1697R	84.2%	POS	13	POS	POS
S35	ND		NEG	-17	NEG	NEG
S36	ND		NEG	0	POS	POS
S37	ND		NEG	6	POS	POS
S38	BRCA1:Y1666*	65.4%	POS	3	POS	POS

Table S2. BRCA mutation status and wGI score of ovarian cancer patients

S39	ND		NEG	-17	NEG	NEG
S40	ND		NEG	4	POS	POS
S41	ND		NEG	-18	NEG	NEG
S42	ND		NEG	-11	NEG	NEG
S43	ND		NEG	-13	NEG	NEG
S44	ND		NEG	-13	NEG	NEG
S45	ND		NEG	-5	NEG	NEG
S46	ND		NEG	-19	NEG	NEG
S47	ND		NEG	-10	NEG	NEG
S48	ND		NEG	-17	NEG	NEG
S49	BRCA1:C274*	82.7%	POS	25	POS	POS
S50	ND		NEG	-16	NEG	NEG
S51	ND		NEG	0	POS	POS
S52	ND		NEG	4	POS	POS
S53	ND		NEG	-12	NEG	NEG
S54	ND		NEG	-3	NEG	NEG
S55	ND		NEG	-13	NEG	NEG
S56	ND		NEG	18	POS	POS
S57	ND		NEG	5	POS	POS
S58	ND		NEG	8	POS	POS
S59	ND		NEG	-12	NEG	POS
S60	BRCA2:G2901Vfs*8	50.0%	POS	-19	NEG	POS
S61	ND		NEG	5	POS	POS
S62	ND		NEG	-16	NEG	POS
S63	ND		NEG	0	POS	POS
S64	ND		NEG	-20	NEG	POS
S65	BRCA1:G1348Nfs*7	62.7%	POS	5	POS	POS
S66	ND		NEG	4	POS	POS
S67	ND		NEG	10	POS	POS
S68	ND		NEG	4	POS	POS
S69	ND		NEG	-16	NEG	NEG
S70	ND		NEG	-13	NEG	NEG
S71	ND		NEG	-19	NEG	NEG
S72	BRCA1:Q541*	80.9%	POS	3	POS	POS
S73	BRCA1:Y1666*	63.6%	POS	7	POS	POS
S74	ND		NEG	7	POS	POS

Abbreviations: ND: not detected, NEG: negative, POS: positive, VAF: variant allele frequency





Α

Figure S2. Data analysis workflow of the HRD INSIGHT assay. (A) The full pipeline illustrated data pre-processing steps including adapter removal, low-quality base trimming, reference genome mapping and QC; followed by analysis for *BRCA1/2* mutations and wGI score as described in the Methods. **(B)** Representative outputs from the pipeline for samples with positive- and negative- wGI scores.

Figure S3. Analytical validation of the HRD INSIGHT assay. Negative- and positiveperformance agreement (NPA and PPA) of the HRD INSIGHT assay with the HRD Focus Panel (AmoyDx), TruSight Oncology TSO 500 HRD (Illumina) and SOPHiA DDM HRD Solutions (Sophia Genetics) to determine (A) *BRCA1/2* mutation status and (B) genomic instability status of clinical FFPE ovarian samples. For conflicting samples, the results of individual assays were shown.

Figure S4. Modification of wet lab protocol improved library yield and successful rate for *BRCA1/2* targeted sequencing. A different set of in-house FFPE DNA samples (n = 20) was used to demonstrate the effectiveness of this modification. Using same DNA input, the DNA library yield (A) and QC measures for *BRCA1/2* targeted sequencing (B) were significantly improved for the modified protocol compared to the standard protocol. (C) QC for sWGS data were not different between the two protocols.